Fifth Third Bancorp Grows Position in Artivion, Inc. $AORT

Fifth Third Bancorp boosted its position in shares of Artivion, Inc. (NYSE:AORT) by 58,029.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 123,235 shares of the company’s stock after buying an additional 123,023 shares during the quarter. Fifth Third Bancorp’s holdings in Artivion were worth $4,513,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AORT. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion in the third quarter worth about $27,000. Rockefeller Capital Management L.P. grew its position in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after acquiring an additional 399 shares during the period. Larson Financial Group LLC increased its stake in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares in the last quarter. USA Financial Formulas raised its holdings in Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the period. Finally, KBC Group NV purchased a new position in Artivion during the fourth quarter worth approximately $65,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on AORT shares. Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Citizens Jmp reduced their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Weiss Ratings cut shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective on the stock in a report on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Artivion has an average rating of “Moderate Buy” and a consensus price target of $44.17.

Artivion Stock Down 2.6%

Shares of AORT opened at $25.07 on Friday. The stock has a 50 day moving average price of $22.46 and a 200 day moving average price of $33.03. Artivion, Inc. has a one year low of $19.16 and a one year high of $48.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of 104.45 and a beta of 1.26.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.